MOLECULAR PARTNERS AG
MOLN · XNASCIK 1745114fmd_102YJ8A1XVNY2AV4S5TQR7WMM9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 12 periods
Latest annual · FY2025
Millions- Total revenues
- 0
- Operating income
- (58)
- Net income
- (62)
- Free cash flow
- (52)
Latest quarter · Q2 FY2025
Millions- Total revenues
- 0
- Operating income
- (17)
- Net income
- (20)
Daily close · MOLNIEX trades only
Mar 16, 2022 to Nov 05, 2026 · 183 sessions3.46 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- n/m
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
MOLECULAR PARTNERS AG (MOLN) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | CHF 0 | CHF 5 million | -100% | 20-F 2026-03-12 · proof |
| Operating income | -CHF 58.1 million | -CHF 61.2 million | 20-F 2026-03-12 · proof | |
| Net income | -CHF 61.7 million | -CHF 54 million | 20-F 2026-03-12 · proof | |
| Cash from operating activities | -CHF 51.3 million | -CHF 59.2 million | 20-F 2026-03-12 · proof | |
| Free cash flow | -CHF 52 million | -CHF 60 million | 20-F 2026-03-12 · proof | |
| Total assets | CHF 102.1 million | CHF 158.5 million | -35.6% | 20-F 2026-03-12 · proof |
| Total liabilities | CHF 21.8 million | CHF 16.9 million | +28.9% | 20-F 2026-03-12 · proof |
| Cash and cash equivalents | CHF 82.7 million | CHF 63.9 million | +29.4% | 20-F 2026-03-12 · proof |
- What was MOLECULAR PARTNERS AG (MOLN)'s revenue in fiscal 2025?
- MOLECULAR PARTNERS AG (MOLN) reported revenue of CHF 0 for fiscal 2025 (the year ended Dec 31, 2025), against CHF 5 million the year before (-100%). Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What was MOLECULAR PARTNERS AG (MOLN)'s operating income in fiscal 2025?
- MOLECULAR PARTNERS AG (MOLN) reported operating income of -CHF 58.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -CHF 61.2 million the year before. Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What was MOLECULAR PARTNERS AG (MOLN)'s net income in fiscal 2025?
- MOLECULAR PARTNERS AG (MOLN) reported net income of -CHF 61.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -CHF 54 million the year before. Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What was MOLECULAR PARTNERS AG (MOLN)'s cash from operating activities in fiscal 2025?
- MOLECULAR PARTNERS AG (MOLN) reported cash from operating activities of -CHF 51.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -CHF 59.2 million the year before. Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What was MOLECULAR PARTNERS AG (MOLN)'s free cash flow in fiscal 2025?
- MOLECULAR PARTNERS AG (MOLN) reported free cash flow of -CHF 52 million for fiscal 2025 (the year ended Dec 31, 2025), against -CHF 60 million the year before. Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What are MOLECULAR PARTNERS AG (MOLN)'s total assets?
- As of Dec 31, 2025, MOLECULAR PARTNERS AG (MOLN) reported total assets of CHF 102.1 million, against CHF 158.5 million a year earlier (-35.6%). Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What are MOLECULAR PARTNERS AG (MOLN)'s total liabilities?
- As of Dec 31, 2025, MOLECULAR PARTNERS AG (MOLN) reported total liabilities of CHF 21.8 million, against CHF 16.9 million a year earlier (+28.9%). Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What are MOLECULAR PARTNERS AG (MOLN)'s cash and cash equivalents?
- As of Dec 31, 2025, MOLECULAR PARTNERS AG (MOLN) reported cash and cash equivalents of CHF 82.7 million, against CHF 63.9 million a year earlier (+29.4%). Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:MOLN&period_type=annual&limit=5"Information only, not investment advice.